Similar articles for PMID: 11034261

Year	Number of Results
1988	1
1990	1
1993	1
1998	6
1999	1
2000	8
2001	2
2002	6
2003	10
2004	12
2005	12
2006	7
2007	5
2008	8
2009	5
2010	4
2011	5
2012	6
2013	4
2014	4
2015	4
2016	2
2019	1
2020	1
2022	1
2023	1
2024	0

1

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Jen JF, et al. Ther Drug Monit. 2000 Oct;22(5):555-65. doi: 10.1097/00007691-200010000-00010. Ther Drug Monit. 2000. PMID: 11034261

2

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group. González-Peralta RP, et al. Hepatology. 2005 Nov;42(5):1010-8. doi: 10.1002/hep.20884. Hepatology. 2005. PMID: 16250032 Clinical Trial.

3

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM. Khakoo S, et al. Br J Clin Pharmacol. 1998 Dec;46(6):563-70. doi: 10.1046/j.1365-2125.1998.00836.x. Br J Clin Pharmacol. 1998. PMID: 9862245 Free PMC article. Clinical Trial.

4

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.

Tsubota A, Akuta N, Suzuki F, Suzuki Y, Someya T, Kobayashi M, Arase Y, Saitoh S, Ikeda K, Kumada H. Tsubota A, et al. Intervirology. 2002;45(1):33-42. doi: 10.1159/000050085. Intervirology. 2002. PMID: 11937769

5

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D. Gallegos-Orozco JF, et al. Rev Invest Clin. 2003 Mar-Apr;55(2):138-42. Rev Invest Clin. 2003. PMID: 12827916

6

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

Buti M, Olive G, Stalgis C, Esteban R, Guardi J. Buti M, et al. Dig Dis Sci. 2000 Apr;45(4):685-9. doi: 10.1023/a:1005479207106. Dig Dis Sci. 2000. PMID: 10759235

7

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.

Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Kamar N, et al. Am J Kidney Dis. 2004 Jan;43(1):140-6. doi: 10.1053/j.ajkd.2003.09.019. Am J Kidney Dis. 2004. PMID: 14712437

8

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H. Tsubota A, et al. J Med Virol. 2005 Jan;75(1):27-34. doi: 10.1002/jmv.20232. J Med Virol. 2005. PMID: 15543591 Clinical Trial.

9

Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Scott LJ, Perry CM. Scott LJ, et al. Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review.

10

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).

Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Poynard T, et al. Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4. Lancet. 1998. PMID: 9807989 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year